Article

Development of major depressive disorder during smoking-cessation treatment.

Miriam Hospital, Division of Behavioral and Preventive Medicine, Providence, RI, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 12/1996; 57(11):534-8.
Source: PubMed

ABSTRACT Several studies have shown an association between smoking and major depressive disorder (MDD), but few have prospectively examined subjects who develop MDD after quitting smoking. This descriptive study evaluated the development of MDD after smoking cessation, as assessed by a structured clinical interview at both baseline and the end of treatment.
Nondepressed participants (N = 114) in a trial investigating the effect of fluoxetine on smoking cessation were administered the Structured Clinical Interview for DSM-III-R at baseline and posttreatment to evaluate the impact of quitting smoking on the development of MDD. Depressive symptoms were additionally assessed with the Beck Depression Inventory and the Hamilton Rating Scale for Depression.
At baseline, 32% of the subjects reported a history of MDD. Sixty-nine subjects completed the SCID at baseline and posttreatment. At posttreatment, 5 subjects (7%) met threshold criteria for MDD; none were taking the highest dose of fluoxetine (60 mg), 4 were taking 30 mg, and 1 was taking placebo. All 5 had a history of MDD; 3 were women. Four had a history of substance abuse and attained at least 3 consecutive biochemically verified weeks of smoking abstinence. Those who developed MDD after treatment scored significantly higher on measures of depressed mood at baseline than those who did not develop MDD after smoking-cessation treatment.
The results from this descriptive study suggest that a subset of smokers may be at risk for developing MDD after smoking cessation.

1 Follower
 · 
81 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The psychological outcomes that accompany smoking cessation are not yet conclusive but positive outcomes could help to persuade quitting.
    Psychological Medicine 09/2014; 44(12):2523-2535. DOI:10.1017/S0033291713003206 · 5.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Alcohol consumption, nicotine use, and major depressive disorder (MDD) are highly co-morbid. The negative reinforcement model of addiction would suggest that smokers may consume alcohol to relieve negative affective symptoms, such as those associated with MDD and withdrawal from nicotine. Over time, these behaviors may become so strongly paired together that they automatically activate a desire to use alcohol, even in the absence of conscious or deliberate intention. This study examined implicit alcohol cognitions in 146 risky drinking nicotine users (n = 83) and non-users (n = 63), to help uncover cognitive mechanisms that link drinking, nicotine use, and depression together. We proposed that nicotine users with a history of MDD would have stronger implicit motivations to drink than non-nicotine users without MDD. Method Participants were assessed on lifetime MDD (n = 84) or no MDD (n = 62), and then completed an Implicit Association Task designed to test the strength of associations between alcohol pictures and “approach” words. Results Regression analyses showed that implicit alcohol–approach attitudes were stronger among risky drinking nicotine users than non-users. Alcohol–approach motivations were also stronger among risky drinking nicotine users compared to non-users with a history of MDD; nicotine use was unrelated to implicit alcohol cognitions for risky drinkers without MDD. Conclusions Implicit cognitive processes may be targeted in behavioral and pharmacological treatments in risky drinking nicotine users, particularly those with depression comorbidity.
    Addictive behaviors 04/2014; 39(4):797–802. DOI:10.1016/j.addbeh.2013.12.012 · 2.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aunque algunas de las consideraciones expuestas a conti-nuación ya han sido parcialmente comentadas en otros capí-tulos, debido a su importancia las exponemos nuevamente aho-ra de forma conjunta por su mejor presentación pedagógica. La elección del método para ayudar a los pacientes a dejar de fumar no cabe duda que debe ser individualizado pues la adaptación del tratamiento al paciente es un factor importan-te en la aceptabilidad y correcta cumplimentación del trata-miento y, por tanto, para la consecución del éxito terapéuti-co. Tampoco se cuestiona que en ausencia de contraindicaciones debemos valorar con el paciente el método farmacológico (chi-cles, parches, bupropión, etc.) que mejor se ajuste a sus necesi-dades y preferencias. Si existe contraindicación para alguna de las modalidades terapéuticas debe informarse al paciente y optar por alguna de las restantes alternativas, en caso de que esté indicado el tratamiento farmacológico. Existen situaciones en las que resulta primordial valorar la relación riesgo beneficio detenidamente antes de prescribir un tratamiento farmacológico. En todo caso, debemos distin-guir entre las contraindicaciones y la posible aparición de efec-tos secundarios. Las contraindicaciones no permiten establecer el tratamiento, mientras que el riesgo de efectos adversos es Manual 211-408 21/4/03 16:51 Página 269 siempre potencial y debe ser tenido en cuenta, pero permite la utilización de la terapia si se considera oportuno. Estos as-pectos han sido ampliamente desarrollados en el capítulo VIII. A continuación exponemos aquellas situaciones que pode-mos encontrar con mayor frecuencia en la consulta en las que pudiera ser necesario realizar un tratamiento de deshabituación tabáquica y que requieren un abordaje particular.